These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 21695286)

  • 21. Nano-Based Drug Delivery System: Recent Strategies for the Treatment of Ocular Disease and Future Perspective.
    Qamar Z; Qizilbash FF; Iqubal MK; Ali A; Narang JK; Ali J; Baboota S
    Recent Pat Drug Deliv Formul; 2019; 13(4):246-254. PubMed ID: 31884933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prominence of the dosage form design to treat ocular diseases.
    Campos PM; Petrilli R; Lopez RFV
    Int J Pharm; 2020 Aug; 586():119577. PubMed ID: 32622806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of nanotechnology in control of human diseases: perspectives in ocular surface diseases.
    Rai M; Ingle AP; Gaikwad S; Padovani FH; Alves M
    Crit Rev Biotechnol; 2016 Oct; 36(5):777-87. PubMed ID: 26189355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendrimers for gene delivery--a potential approach for ocular therapy?
    Chaplot SP; Rupenthal ID
    J Pharm Pharmacol; 2014 Apr; 66(4):542-56. PubMed ID: 24635556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modern drug delivery systems for targeting the posterior segment of the eye.
    Peptu CA; Popa M; Savin C; Popa RF; Ochiuz L
    Curr Pharm Des; 2015; 21(42):6055-69. PubMed ID: 26503152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nano-based eye drop: Topical and noninvasive therapy for ocular diseases.
    Wang C; Pang Y
    Adv Drug Deliv Rev; 2023 Mar; 194():114721. PubMed ID: 36773886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug delivery to the eye: what benefits do nanocarriers offer?
    Joseph RR; Venkatraman SS
    Nanomedicine (Lond); 2017 Mar; 12(6):683-702. PubMed ID: 28186436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanocarriers in ocular drug delivery: an update review.
    Wadhwa S; Paliwal R; Paliwal SR; Vyas SP
    Curr Pharm Des; 2009; 15(23):2724-50. PubMed ID: 19689343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of Recent Advances in Nano-Based Ocular Drug Delivery.
    Liu LC; Chen YH; Lu DW
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanotherapy for posterior eye diseases.
    Kaur IP; Kakkar S
    J Control Release; 2014 Nov; 193():100-12. PubMed ID: 24862316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in ocular drug delivery.
    Rawas-Qalaji M; Williams CA
    Curr Eye Res; 2012 May; 37(5):345-56. PubMed ID: 22510004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-invasive strategies for targeting the posterior segment of eye.
    Madni A; Rahem MA; Tahir N; Sarfraz M; Jabar A; Rehman M; Kashif PM; Badshah SF; Khan KU; Santos HA
    Int J Pharm; 2017 Sep; 530(1-2):326-345. PubMed ID: 28755994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dendrimers as a promising tool in ocular therapeutics: Latest advances and perspectives.
    Rodríguez Villanueva J; Navarro MG; Rodríguez Villanueva L
    Int J Pharm; 2016 Sep; 511(1):359-366. PubMed ID: 27436708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review on recent drug delivery systems for posterior segment of eye.
    Nayak K; Misra M
    Biomed Pharmacother; 2018 Nov; 107():1564-1582. PubMed ID: 30257375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanotechnology approaches for ocular drug delivery.
    Xu Q; Kambhampati SP; Kannan RM
    Middle East Afr J Ophthalmol; 2013; 20(1):26-37. PubMed ID: 23580849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trends in Formulation Approaches for Sustained Drug Delivery to the Posterior Segment of the Eye.
    Biswas A; Choudhury AD; Bisen AC; Agrawal S; Sanap SN; Verma SK; Mishra A; Kumar S; Bhatta RS
    AAPS PharmSciTech; 2023 Oct; 24(8):217. PubMed ID: 37891392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches.
    Agrahari V; Agrahari V; Mandal A; Pal D; Mitra AK
    Expert Opin Drug Deliv; 2017 Oct; 14(10):1145-1162. PubMed ID: 27967247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits.
    Chetoni P; Burgalassi S; Monti D; Tampucci S; Tullio V; Cuffini AM; Muntoni E; Spagnolo R; Zara GP; Cavalli R
    Eur J Pharm Biopharm; 2016 Dec; 109():214-223. PubMed ID: 27789355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanoformulations and Highlights of Clinical Studies for Ocular Drug Delivery Systems: An Overview.
    Momin MM; Afreen SD
    Crit Rev Ther Drug Carrier Syst; 2021; 38(4):79-107. PubMed ID: 34369740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel nanosystems for the treatment of ocular inflammation: Current paradigms and future research directions.
    Lalu L; Tambe V; Pradhan D; Nayak K; Bagchi S; Maheshwari R; Kalia K; Tekade RK
    J Control Release; 2017 Dec; 268():19-39. PubMed ID: 28756272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.